SCHEDULE: Avoro Capital Advisors Discloses 9.38% Stake in Structure Therapeutics

Avoro Capital Advisors LLC and Behzad Aghazadeh have reported a 9.38% beneficial ownership stake in Structure Therapeutics Inc. as of September 30, 2025.

Summary

• Avoro Capital Advisors LLC and Behzad Aghazadeh collectively reported beneficial ownership of 16,216,665 Ordinary Shares of Structure Therapeutics Inc.
• This represents 9.38% of the company's Ordinary Shares outstanding.
• The calculation is based on 172,793,818 Ordinary Shares outstanding as of July 31, 2025, as reported in Structure Therapeutics Inc.'s Quarterly Report on Form 10-Q.
• The reported shares include 750,000 Ordinary Shares (represented by 250,000 ADSs) issuable upon the exercise of options.
• The investment is held solely for investment purposes and not to influence control of the issuer.
• Avoro Capital Advisors LLC, a Delaware limited liability company, provides investment advisory and management services.
• Behzad Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors.
• The securities are held on behalf of Avoro Life Sciences Fund LLC.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive investment by a reputable investment advisor like Avoro Capital Advisors can be viewed positively by the market, indicating confidence in Structure Therapeutics Inc.

Positives

• A significant institutional investor, Avoro Capital Advisors LLC, has taken a substantial 9.38% stake in Structure Therapeutics Inc., signaling confidence in the company.
• The investment is explicitly stated to be for passive investment purposes, not for seeking control, which can reduce concerns about potential activist interventions.

Future Outlook

This filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance from Structure Therapeutics Inc. or the reporting persons regarding the company's future performance or strategy.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Industry Context

This filing reflects a standard institutional investment disclosure in the biotechnology or pharmaceutical sector, where Structure Therapeutics Inc. operates (indicated by the 'GPCR' trading symbol, often associated with G protein-coupled receptor research). Such significant passive stakes by specialized life sciences funds are common and can be interpreted as a vote of confidence in the company's potential.

Comparison to Industry Standards

• This filing is a regulatory disclosure of beneficial ownership and does not provide operational or financial results that can be directly compared to global industry benchmarks or specific comparable companies/projects. The act of an institutional investor taking a significant stake is a common practice across industries.

Related Party Transactions

• Avoro Life Sciences Fund LLC is identified as the entity for whom Avoro Capital Advisors LLC manages the investment and has the right to receive dividends or proceeds from the sale of securities. This is an internal relationship within the Avoro structure, not a related party transaction with Structure Therapeutics Inc.

Stakeholder Impact

• Shareholders may view the disclosure of a significant stake by a prominent institutional investor as a positive signal, potentially increasing market confidence and demand for Structure Therapeutics Inc.'s shares.
• Management and the board of Structure Therapeutics Inc. will be aware of this substantial passive shareholder, which could influence future strategic considerations, though the filing explicitly states no intent to influence control.

Key Dates

Recommendation

The filing indicates a significant passive investment by Avoro Capital Advisors, a respected institutional investor. While this signals confidence, the filing does not contain operational or financial performance data to warrant a 'buy' or 'sell' recommendation. It primarily serves as a disclosure of a substantial stake, which is generally a positive indicator for current shareholders to 'hold'.

Keywords

Structure Therapeutics Inc., Avoro Capital Advisors LLC, Behzad Aghazadeh, Schedule 13G, Beneficial Ownership, Institutional Investment, GPCR, Ordinary Shares, ADSs, Investment Fund